IMW 2019 | Elotuzumab with Car/Pom/Dex for high-risk R/R myeloma

James Berenson

Here, James Berenson, MD, from The Institute for Myeloma & Bone Cancer Research, West Hollywood, CA, discusses the Phase II study (NCT0310427) of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for patients with high-risk R/R myeloma. Dr Berenson was speaking at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

Share this video